
Udo Rudloff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8204437/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Science Translational Medicine, 2020, 12, .	12.4	205
2	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. American Journal of Human Genetics, 2016, 98, 830-842.	6.2	201
3	Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. Journal of Surgical Oncology, 2014, 110, 275-284.	1.7	159
4	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
5	Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut, 2013, 62, 1777-1786.	12.1	91
6	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	12.4	55
7	Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clinical and Experimental Gastroenterology, 2018, Volume 11, 447-459.	2.3	40
8	A growing family: Adding mutated Erbb4 as a novel cancer target. Cell Cycle, 2010, 9, 1487-1503.	2.6	34
9	Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). Journal of Medical Genetics, 2019, 56, 370-379.	3.2	33
10	The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. Clinical Infectious Diseases, 2018, 66, 1427-1434.	5.8	31
11	Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin. Journal of Cancer, 2016, 7, 1142-1151.	2.5	28
12	Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review. Journal of Surgical Oncology, 2017, 115, 192-201.	1.7	25
13	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Investigational New Drugs, 2021, 39, 821-828.	2.6	24
14	Merging perspectives: genotypeâ€directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and Eâ€cadherin–EGFR crosstalk. Clinical and Translational Medicine, 2018, 7, 7.	4.0	22
15	Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS ONE, 2016, 11, e0149833.	2.5	21
16	β-Catenin activation in fundic gland polyps, gastric cancer and colonic polyps in families afflicted by †gastric adenocarcinoma and proximal polyposis of the stomach' (GAPPS). Journal of Clinical Pathology, 2016, 69, 826-833.	2.0	20
17	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time?. Journal of Gastrointestinal Oncology, 2016, 7, 87-98.	1.4	18
18	Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. BMC Cancer, 2018, 18, 772.	2.6	17

UDO RUDLOFF

#	Article	IF	CITATIONS
19	Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype. Molecular Cancer Therapeutics, 2019, 18, 2097-2110.	4.1	16
20	Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. Journal of Translational Medicine, 2017, 15, 92.	4.4	14
21	Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. BMC Cancer, 2017, 17, 495.	2.6	10
22	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 1067-1080.	2.3	9
23	T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1926-1940.	4.1	9
24	Metabolism and pharmacokinetics characterization of metarrestin in multiple species. Cancer Chemotherapy and Pharmacology, 2020, 85, 805-816.	2.3	6
25	Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells. Regulatory Toxicology and Pharmacology, 2020, 116, 104716.	2.7	4
26	Mini-Review: PDPK1 (3-phosphoinositide dependent protein kinase-1), An Emerging Cancer Stem Cell Target. Journal of Cancer Treatment & Diagnosis, 2021, 5, 30-35.	0.9	4
27	Teaching principles of translational science to a broad scientific audience using a case study approach: A pilot course from the National Center for Advancing Translational Sciences. Journal of Clinical and Translational Science, 2022, 6, .	0.6	4
28	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	6.4	4
29	Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review. International Journal of Hyperthermia, 2018, 34, 501-511.	2.5	2
30	LC-MS/MS assay coupled with carboxylic acid magnetic bead affinity capture to quantitatively measure cationic host defense peptides (HDPs) in complex matrices with application to preclinical pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113093.	2.8	1